Researchers track Long-Term safety of experimental eye cancer drug

NCT ID NCT03941379

Ongoing Knowledge-focused Sponsor: Aura Biosciences Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This registry follows 63 patients with choroidal melanoma or early eye lesions who were treated with the experimental drug bel-sar in earlier studies. The goal is to monitor long-term safety, side effects, and any spread of the disease over time. Participants are not receiving new treatment but are observed through standard medical checkups.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: bel-sar (AU-011)
What this could lead to: If successful, this registry will provide important long-term safety data that could support the future use of bel-sar as a treatment for choroidal melanoma.
What could go wrong: This is an observational registry, not a treatment trial, so it does not test whether bel-sar works. It only collects data from a small number of patients who already received the drug.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

malignant choroid melanoma Uveal Melanoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHOROIDAL MELANOMA INDETERMINATE LESIONS OF EYE

Contacts and locations

Show contact details

Locations

Associated Retinal Consultants, PC

Royal Oak, Michigan, 48073, United States
Byers Eye Institute at Stanford University

Palo Alto, California, 94303, United States
Columbia University Medical Center

New York, New York, 10032, United States
Massachusetts Eye and Ear Infirmary

Boston, Massachusetts, 02114, United States
Oregon Health & Science University Casey Eye Institute

Portland, Oregon, 97239, United States
Retina Associates SW, P.C.

Tucson, Arizona, 85710, United States
Retina Center

Minneapolis, Minnesota, 55404, United States
Retina Consultants of Carolina, PA

Greenville, South Carolina, 29605, United States
Retina Consultants of Houston

Houston, Texas, 77030, United States
Retina Consultants of Sacramento

Sacramento, California, 95825, United States
St. Thomas Health / Tennessee Retina, PC

Nashville, Tennessee, 37203, United States
Texas Retina Associates

Dallas, Texas, 75231, United States
UCLA Jules Stein Eye Institute

Los Angeles, California, 90095, United States
University of Wisconsin

Madison, Wisconsin, 53705, United States
W. K. Kellogg Eye Center, University of Michigan

Ann Arbor, Michigan, 48105, United States
Wills Eye Hospital

Philadelphia, Pennsylvania, 19107, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.